Loading…
Belite Bio, Inc is projected to rise to $182.10 by 2027, a +28% move from its current price of $142.09. BLTE is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $139.05 | $142.17 | $145.36 | +0.05% |
| May 30 | $137.85 | $142.24 | $146.78 | +0.11% |
| May 31 | $136.95 | $142.32 | $147.89 | +0.16% |
| Jun 1 | $136.21 | $142.39 | $148.85 | +0.21% |
| Jun 2 | $135.57 | $142.47 | $149.71 | +0.26% |
| Jun 3 | $135.00 | $142.54 | $150.50 | +0.32% |
| Jun 4 | $134.48 | $142.62 | $151.24 | +0.37% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $134.48 | $142.62 | $151.24 | +0.37% |
| Week 2 | $131.74 | $143.15 | $155.54 | +0.74% |
| Week 3 | $129.78 | $143.68 | $159.06 | +1.12% |
| Week 4 | $128.23 | $144.21 | $162.18 | +1.49% |
| Week 5 | $126.94 | $144.75 | $165.05 | +1.87% |
| Week 6 | $125.82 | $145.28 | $167.76 | +2.25% |
| Week 7 | $124.84 | $145.82 | $170.33 | +2.63% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Belite Bio, Inc is a clinical stage biopharmaceutical drug development company focused on research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered therapy in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an retinol binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout.
Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
Belite Bio, Inc (BLTE) currently trades at $137.30 with a market capitalization of $5.5B and is ranked 1275. The stock’s near-term picture shows bullish sentiment with a price near key levels and a 30-day trading range that provides context for potential moves. The forecast landscape points to a meaningful long-term upside, with projected average prices that rise through the late 2020s and into the 2030s and beyond, accompanied by rising ROIs.
A major floor 17.0% below — a decisive break under it would weaken the trend.
The nearest floor, 3.4% below — buyers have tended to step in here.
The nearest ceiling, 18.8% above — a clean break opens room to run.
A major ceiling 33.9% above — clearing it would confirm fresh momentum.
Key BLTE support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of BLTE market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $141.80 | Buy | $142.02 | Buy |
| MA 10 | $143.81 | Sell | $144.25 | Sell |
| MA 20 | $149.50 | Sell | $148.79 | Sell |
| MA 50 | $157.74 | Sell | $155.90 | Sell |
| MA 100 | $164.42 | Sell | $153.79 | Sell |
| MA 200 | $132.29 | Buy | $136.41 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 38.44 | Neutral |
| Stoch RSI (14) | 61.61 | Neutral |
| CCI (20) | -80.47 | Neutral |
| Williams %R (14) | -74.39 | Info |
| MACD (12,26,9) | -0.58 | Sell |
| ROC (12) | -8.26 | Sell |
| Bollinger %B (20,2) | 0.22 | Neutral |
| Stochastic %K (14) | 25.61 | Neutral |
| TRIX (15) | -0.47 | Sell |
| Awesome (5,34) | -14.87 | Sell |
| Ultimate (7,14,28) | 42.15 | Neutral |
| Momentum (10) | -13.45 | Sell |
| Aroon Osc (25) | -88.00 | Sell |
| Hull MA (9) | 140.27 | Buy |
| ADX (14) | 22.12 | Sell |
| ATR (14) | 3.05 | Info |
Technical sentiment is BULLISH, with RSI(14) at 30. The stock is trading above the 200-day SMA of $131.57 but below the 50-day SMA of $158.65, indicating mixed near-term momentum. Support is listed at $137.30 and resistance at $173.18. In the last 30 days, the price has traded between $118.26 and $159.41, highlighting a wide but upward-bias range.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $137.30 | $142.09 | $193.19 | 0% | Neutral | |
| $147.05 | $182.10 | $237.26 | +28% | Bullish | |
| $155.93 | $197.31 | $264.85 | +39% | Bullish | |
| $171.42 | $220.86 | $303.57 | +55% | Bullish | |
| $194.06 | $254.03 | $356.27 | +79% | Bullish | |
| $231.11 | $306.94 | $438.17 | +116% | Bullish | |
| $271.70 | $365.73 | $530.49 | +157% | Bullish | |
| $293.84 | $400.54 | $589.49 | +182% | Bullish | |
| $326.75 | $450.74 | $672.32 | +217% | Bullish | |
| $341.82 | $476.93 | $720.32 | +236% | Bullish | |
| $556.32 | $816.98 | $1,300.73 | +475% | Bullish | |
| $923.24 | $1,478.14 | $2,543.75 | +940% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $137.30 | $142.09 | $166.61 | +0.00% |
| June 2026 | $124.54 | $145.67 | $173.98 | +2.52% |
| July 2026 | $126.62 | $149.12 | $180.07 | +2.37% |
| August 2026 | $124.92 | $147.89 | $180.12 | -0.82% |
| September 2026 | $124.68 | $148.26 | $181.82 | +0.25% |
| October 2026 | $128.39 | $153.28 | $189.16 | +3.39% |
| November 2026 | $129.94 | $155.68 | $193.18 | +1.57% |
| December 2026 | $128.83 | $154.89 | $193.19 | -0.51% |
Click any year to see its month-by-month BLTE forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, BLTE could reach as high as $193.19, with a base case around $142.09 and support toward $137.30 — roughly 0% from $142.09. Price action looks broadly range-bound.
Expect BLTE to range from $147.05 to $237.26 through 2027. The $182.10 average target implies a +28% move from current prices. That is up +28% on the projected 2026 average. Buyers look set to stay in control over this stretch.
The BLTE price prediction for 2028 points to an average of $197.31 (low $155.93, high $264.85) — a potential gain of +39% on today's $142.09. Momentum favours further upside here.
In 2029, BLTE is projected to trade between $171.42 and $303.57, averaging $220.86 — a potential gain of +55% from today's $142.09. That is up +12% on the projected 2028 average. Buyers look set to stay in control over this stretch.
Belite Bio, Inc's 2030 outlook centres on $254.03, within a $194.06 to $356.27 range. That is up +15% on the projected 2029 average. That marks a +79% change versus current levels. Momentum favours further upside here.
By 2031, BLTE could reach as high as $438.17, with a base case around $306.94 and support toward $231.11 — roughly +116% from $142.09. Buyers look set to stay in control over this stretch.
Expect BLTE to range from $271.70 to $530.49 through 2032. The $365.73 average target implies a +157% move from current prices. That is up +19% on the projected 2031 average. Momentum favours further upside here.
The BLTE price prediction for 2033 points to an average of $400.54 (low $293.84, high $589.49) — a potential gain of +182% on today's $142.09. Buyers look set to stay in control over this stretch.
In 2034, BLTE is projected to trade between $326.75 and $672.32, averaging $450.74 — a potential gain of +217% from today's $142.09. That is up +13% on the projected 2033 average. Momentum favours further upside here.
Belite Bio, Inc's 2035 outlook centres on $476.93, within a $341.82 to $720.32 range. That is up +6% on the projected 2034 average. That marks a +236% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, BLTE could reach as high as $1,300.73, with a base case around $816.98 and support toward $556.32 — roughly +475% from $142.09. Momentum favours further upside here.
Expect BLTE to range from $923.24 to $2,543.75 through 2050. The $1,478.14 average target implies a +940% move from current prices. That is up +81% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in BLTE today (≈ 7.037793 BLTE) could be worth
$10,402.81
+$9,402.81 (+940%) by 2050 · US Dollar
Based on the average projected BLTE price of $1,478.14 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in BLTEwould be worth at today's price.
$1,000 invested in BLTE on May 27, 2025 (≈ 16.225864 BLTE) would be worth
$2,305.53
+$1,305.53 (+130.6%) today · 2.31× · US Dollar
Based on a BLTE entry price of $61.63 vs. today's $142.09.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $143.36 | $991.14 | -0.9% |
| 1 month ago | $163.06 | $871.4 | -12.9% |
| 3 months ago | $188.55 | $753.59 | -24.6% |
| 6 months ago | $137.44 | $1,033.83 | +3.4% |
| 1 year ago | $61.63 | $2,305.53 | +130.6% |
| All time (4.1y) ago | $10.59 | $13,417.37 | +1241.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our BLTE forecast.
Our base-case forecast reaches $280.00 around 2031.
Implied market cap at $280.00: $11.22B
The multi-year forecast shows a gradually expanding price path. In 2026, the average is $137.30 with a max of $185.53 (min $137.30) and neutral sentiment. By 2027 the average rises to $172.66 with a max of $225.58 and a bullish tilt, followed by 2028 at $182.50 (max $245.74), 2029 at $201.82 (max $278.38), and 2030 at $230.60 (max $324.65) with a 68% ROI.
The trajectory continues to 2040, where the average is $685.29 (max $1,097.32) and a 399.1% ROI, and reaches 2050 with an average of $1,210.45 (max $2,097.26) and a 781.6% ROI. Across these years, sentiment remains bullish, reflecting an expected sustained upward pricing path though these are estimates, not guarantees, and subject to market and company-specific factors.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $230.60 with a max of $324.65 and a min of $175.62, along with a projected ROI of 68% and a bullish sentiment.
Forecasts show bullish sentiment from 2027 onward with rising average prices and ROIs (e.g., 25.8% in 2027 rising to 68% in 2030, then to 399.1% by 2040 and 781.6% by 2050). These are estimates, not guarantees, and depend on market conditions and company developments.
Yes, the 2050 forecast lists a max of $2,097.26, indicating a path where $2,000 could be touched in a high-case scenario.
Current price is $137.30 and market cap is $5.5B. The stock is ranked 1275.
The 30-day range is $118.26 to $159.41, with current support listed at $137.30 and resistance at $173.18.
Belite Bio, Inc Community Discussion
0Share your Belite Bio, Inc price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.